Aveni Foundation

The Aveni Foundation is a non-profit biotechnology organization dedicated to accelerating the development of breakthrough gene therapies for cancer and other unmet medical needs. The foundation's lead program is Rexin-G, a tumor-targeted retroviral vector designed to deliver a genetic payload that interrupts the cell cycle in cancer cells by targeting the Cyclin G1 gene. Rexin-G has shown clinical activity in various solid tumors, including pancreatic cancer, sarcoma, and osteosarcoma, and has received Orphan Drug and Fast Track designations from the FDA. Aveni Foundation operates by bridging the gap between academic research and commercial development, utilizing a unique non-profit model to bring life-saving treatments to patients more efficiently. The organization is led by a team of experienced oncologists and gene therapy pioneers who focus on pathotropic (disease-seeking) targeting technologies.